<DOC>
	<DOCNO>NCT01531699</DOCNO>
	<brief_summary>This open-label , randomize , single-dose , placebo-controlled efficacy study assess antimicrobial efficacy ALT005 ophthalmic prep solution follow dermal administration healthy volunteer . Efficacy assess compare reduction microbial load 6 hour saline control .</brief_summary>
	<brief_title>Antimicrobial Efficacy ALT005 Ophthalmic Prep Solution Healthy Volunteers</brief_title>
	<detailed_description>A total 45 subject meet criterion inclusion receive either ALT005 control solution ( sterile 0.9 % saline ) one occasion sit forehead cheek . Subjects randomize ratio 2:1 active : control . Subjects dose group . The study run one study center US . Subjects house clinical research facility morning Day -4 even Day 1 . The total duration participation subject dose approximately 21 day ( Day -19 study orientation follow-up call Day 2 , exclude initial screening period ) . In study , efficacy ALT005 assess healthy volunteer , refrain voluntarily use topical oral antimicrobial least 2 week ( 14 day ) , exhibit acceptably high normal flora count designate skin test site . An additional cohort add ( 3 ALT005 , 6 Comparator Product ) make non-statistical comparison efficacy .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Povidone-Iodine</mesh_term>
	<criteria>Medically healthy clinically significant finding screen result Nontobacco/nicotinecontaining product user Acceptably high normal ( &gt; 3 log10 ) flora count designate skin site Day 4 . Voluntarily consent participate study . Females report spontaneous postmenopausal status WOCBP must either sexually inactive ( abstinent ) 14 day prior screen remain 30 day follow administration ( topical dosing ) study drug use acceptable method birth control time specify WOCBP undergone sterilization procedure 6 month prior Day 1 History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic ( include sensitive skin face ) , neurological , psychiatric disease , clinically significant disease deem acceptable PI . Evidence compromise skin integrity forehead cheek cause acute rash , exacerbation dermatitis , exacerbation acne , acute condition deem clinically significant PI . Tattoo , scar , keloid , chronic skin condition locate forehead cheek Facial hair growth would interfere sample collection procedure . Positive urine drug/alcohol cotinine test Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . History presence alcoholism drug abuse within 2 year prior Day 1 . Hypersensitivity idiosyncratic reaction ingredient ALT005 . Use prescription medication start within 90 day prior Day 1 Use overthecounter ( OTC ) medication , include herbal product , within 14 day prior Day 1 Blood donation significant blood loss within 56 day prior Day 1 Plasma donation within 7 day prior Day 1 Participation another clinical trial within 30 day prior Day 1 Females pregnant lactating , positive pregnancy test screen checkin Failure comply pretreatment restriction relate showering/washing contact antimicrobial substance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>